Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance

Semin Roentgenol. 2014 Jul;49(3):238-41. doi: 10.1053/j.ro.2014.09.001. Epub 2014 Sep 16.

Authors

Laia Valls¹, Christopher Hoimes², Andrew Sher¹, Lingzhi Hu³, Zhenghong Lee¹, Raymond Muzic¹, Norbert Avril⁴

Affiliations

¹ Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
² Department of Medicine, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
³ Advanced Molecular Imaging, Philips Healthcare North America, Cleveland, OH.
⁴ Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH. Electronic address: [email protected].

PMID: 25497908
DOI: 10.1053/j.ro.2014.09.001

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoma, Renal Cell / diagnosis
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / secondary*
Contrast Media
Diffusion Magnetic Resonance Imaging
Gadolinium DTPA
Humans
Image Enhancement
Indoles / therapeutic use
Kidney Neoplasms / diagnosis*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / secondary
Magnetic Resonance Spectroscopy*
Male
Middle Aged
Multimodal Imaging
Positron-Emission Tomography*
Protein Kinase Inhibitors / therapeutic use*
Pyrroles / therapeutic use
Radiopharmaceuticals
Sunitinib
Tomography, X-Ray Computed
Treatment Outcome
Tyrosine / analogs & derivatives

Substances

Antineoplastic Agents
Contrast Media
Indoles
Protein Kinase Inhibitors
Pyrroles
Radiopharmaceuticals
(18F)fluoroethyltyrosine
Tyrosine
Gadolinium DTPA
Sunitinib

Grants and funding

UL1 TR000439/TR/NCATS NIH HHS/United States